A small molecule compound targeting uqcrc1 and its application in resisting pancreatic cancer
By developing the small molecule compound Dichlotrizole targeting UQCRC1, the problems of poor efficacy and high toxicity of existing pancreatic cancer drugs have been solved. This approach achieves effective inhibition of pancreatic cancer cells and safety for normal cells, providing a new biological drug treatment option.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- THE SECOND AFFILIATED HOSPITAL ARMY MEDICAL UNIV
- Filing Date
- 2026-05-27
- Publication Date
- 2026-07-14
AI Technical Summary
Existing pancreatic cancer treatments are ineffective and have significant side effects. Furthermore, there is a lack of small-molecule targeted drugs specifically targeting UQCRC1, making it difficult to effectively inhibit the growth of pancreatic cancer cells and affect normal cells.
A small molecule compound, Dichlotrizole, targeting UQCRC1, was developed to inhibit the activity and proliferation of pancreatic cancer cells. By inhibiting the UQCRC1 pathway and p-Akt phosphorylation, it can be prepared into various dosage forms such as injections, pills, capsules, granules, tablets, or oral liquids.
Dichlotrizole significantly inhibits the growth and proliferation of pancreatic cancer cells, while exhibiting no toxicity to normal cells. This provides a new direction for anti-pancreatic cancer biopharmaceutical therapy, demonstrating selectivity and safety.
Smart Images
Figure CN122376586A_ABST